Trajectories›Antimicrobial resistance mortality through 2050
Antimicrobial resistance mortality through 2050
Grey rhino2025–2050WHO 2023 / IACG
Drug-resistant infections already kill 1.3 million people annually — the drug pipeline is nearly empty because the economics don't work.
The WHO and the Interagency Coordination Group on AMR project 10 million deaths per year by 2050 under a do-nothing scenario — exceeding cancer mortality. The economic incentive for antibiotic R&D is broken: antibiotics are cheap, short-course, and prescribed sparingly. Only 2–3 novel classes have entered clinical use since 1980. Three variants: intervention (push/pull funding, antibiotic stewardship, surveillance networks); incremental response; pipeline failure (current trajectory).
Projections from WHO GLASS surveillance, the O'Neill Review on AMR, and IACG reports. Mortality estimates carry wide uncertainty bands.
Annual deaths attributable to AMR (millions)
Source: WHO GLASS 2023 · O'Neill Review on AMR · IACG 2019 final report
Global intervention
O'Neill Review intervention scenario · minority
Incremental response
WHO GLASS BAU-with-stewardship · consensus · most likely
Pipeline failure⚠
IACG do-nothing scenario · contested · most impactful
Key indicators
Today~1.4M
Peak year2050
Inflection2035–2042
Range by end2.8–10M
Spread (most-least)7.2M
Line style encodes source authority. Color matches line color in the chart.
Most likely outcome
Incremental response
Current stewardship programs slow but do not reverse the trend. 6 million deaths annually by 2050 — roughly equivalent to today's cancer mortality. Healthcare systems in low-income countries bear disproportionate burden.
Most impactful if it happens
Pipeline failure
No new drug classes, no coordinated global response. 10 million deaths annually by 2050. Routine surgeries and cancer chemotherapy become life-threatening. Pandemic preparedness frameworks fail to address AMR as a co-crisis.
Insufficient signal — fewer than 3 distinct sources in the 7-day window. Weighted lean suppressed.
Reform / policy signals
0 signals · 0.0 w
Macro stress signals
0 signals · 0.0 w
Tail-risk signals
0 signals · 0.0 w
Global intervention
Push/pull funding (subscription models, Pasteur Act equivalent) + global surveillance + stewardship protocols reduce mortality growth to 2.8M by 2050.
Trade lens — Novel antibiotic pipeline stocks (Iterion, Nabriva, Forge Biologics) re-rate on pull-incentive legislation; diagnostics companies (bioMérieux, Cepheid) gain from surveillance mandates · structural
Incremental response
Stewardship programs and national action plans slow resistance growth but fail to reverse pipeline economics. 6M deaths annually by 2050.
Trade lens — Hospital infection-control vendors (BD, Becton) benefit from stewardship mandates; generic antibiotic manufacturers face pricing pressure as resistance renders legacy drugs ineffective · slow / structural
Pipeline failure
No new drug classes enter use. Pan-resistant pathogens spread in healthcare settings globally. Surgical mortality reverts toward pre-antibiotic levels.
Trade lens — Phage therapy and CRISPR-antimicrobial platforms re-rate as last-resort alternatives; hospital supply-chain companies (Owens & Minor, Medline) benefit from infection-control infrastructure spend · fast / meaningful
Companies — winners & losers
▲ Winners
bioMérieuxBIM.PA
Rapid diagnostics reduce inappropriate antibiotic use and identify resistant pathogens faster; demand grows across all scenarios.
Becton DickinsonBDX
Infection-control and diagnostics product lines benefit from hospital stewardship mandates.
Cepheid (Danaher)DHR(intervention)
Point-of-care molecular diagnostics; rapid ID of resistant strains drives adoption in emergency settings.
▼ Losers
PfizerPFE(pipeline failure)
Generic antibiotic revenues at risk as legacy drugs lose efficacy; pipeline economics make replacement investment unattractive.
Johnson & JohnsonJNJ(pipeline failure)
Surgical procedure revenue threatened if post-surgical infection risk rises to pre-antibiotic levels.
Countries — winners & losers
▲ Winners
🇸🇪Sweden
Global leader in antibiotic stewardship; model for national action plan design and surveillance capacity.
🇬🇧United Kingdom(intervention)
NHS subscription model for antibiotics is the world's first pull-incentive implementation; positions UK pharma favorably.
▼ Losers
🇮🇳India
Highest AMR burden globally; pharmaceutical manufacturing hub also drives resistance through effluent from production sites.
🇳🇬Nigeria(pipeline failure)
High disease burden, weak surveillance, limited stewardship capacity — disproportionately affected under all non-intervention scenarios.
🇨🇳China(pipeline failure)
World's largest antibiotic consumer; agricultural AMR spillover into human health systems is a structural risk.
What would shift our prior
Novel antibiotic class entering Phase 3 trials · pull-incentive legislation passing in US + EU + UK simultaneously · WHO GLASS reporting coverage reaching 80% of countries · sustained decline in ESKAPE pathogen resistance rates across two WHO surveillance cycles · CARB-X pipeline advancing 3+ priority candidates to Phase 2
Our internal forecast ledger tracks dated probability commitments — see /forecasts for the record we hold ourselves to. Methodology lives at /scenarios/methodology.